Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.
Nine patients with malignant glioma were treated with the lymphokine interleukin-2 (IL-2) or with lymphokine-activated killer (LAK) cells, and one patient received combination therapy with both LAK cells and IL-2. The LAK cells were generated by culturing recombinant IL-2 with peripheral blood lymphocytes obtained from brain-tumor patients. Escalating doses of LAK cells (10(8) to 10(10] or IL-2 (10(4) to 10(6) U) were administered intraoperatively by direct injection into the brain tissue surrounding the cavity left by debulking the tumor. There were no signs of systemic or neural toxicity following treatment. The selective killing of the tumor by LAK cells used for these treatments was demonstrated by a chromium release microcytotoxicity assay which showed in vitro the ability of the LAK cells to lyse glioma cells but not normal cells.
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D005260:Female; D005910:Glioma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use*; D007694:Killer Cells, Natural; D008297:Male; D008875:Middle Aged
D007376:Interleukin-2